Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You talk some ****
You talk some ****
Revenues £50m without Covid
ORPH PR have now got back with a curate's eggish explanation about CHIMagents :
"..The acquisition of CHIMagents was completed and announced via RNS on 14 July 2021 (https://www.londonstockexchange.com/news-article/ORPH/new-contract-win-for-open-orphan-s-breda-office/15057797).
Adrian is now a full-time employee of hVIVO and what appears on Companies House is a result of the paperwork still being processed as part of the recent acquisition..."
So Wildfire (and CHIMagents) IS on board (good !), the paperwork processing is taking its time (over 3 months...not so good).
HTH
Hi Greend100,
Thanks for this ! I didn't see the CHIMagents footnote to the Breda contract news....;-<
Companies House shows CHIMagents Limited as being incorporated in June 2020 and in a confirmation statement June 2021 named 6 individuals as shareholders, Wildfire and Schutten each having 60 of the 200 share capital.
Have they /ORPH just been remiss in reporting 'subsequent developments' ?
Apart from CHIMagents, Companies House also has Wildfire has a Director (since Nov 2020) of PrepBioPharm. He is reported as having joined hVivo in July 2020 and is described as a director of hVivo in an article written for Drug Discovery Today in January 2021.
All a bit confusing , to me . Any further insight/clarification ?
TIA
This was in the 14th July RNS
Completion of CHIMagents acquisition
Separately, and further to the Company's announcement of 15 July 2020, Open Orphan announces that it has completed its acquisition of CHIMagents Limited. CHIMagents was established to assist in the design, manufacture and testing of challenge agents for use in challenge studies. The CHIMagents team have been working alongside the
Open Orphan team since July 2020 supporting the design, manufacture and testing of both new challenge agents and the Company's industry leading portfolio of existing challenge study agents.
Bloody cut and paste - you get the idea of where I’m coming from :-)
Hi Extrader, my understanding of timings from what has been said…delta strain is being manufactured by Nov/Dec to support characterisation study on Delta (alpha done, just awaiting report which seems likely early Nov based on comments from Dr Chiu). I’m assuming they’ll continue manufacturing it to support private sector anti viral trials next year and challenge studies post characterisation. Characterisation for delta would be Jan-May(ish) and CF has already mentioned that they’ve agreed c £5-6mn on top of the non-Covid £50mn for next FY from the characterisation work in H1, so timing for H2 to start running challenge trials seems realistic, although frustrating.
May also be why he is talking up anti viral work which could run off alpha characterisation?
Key part for me in the Telegraph article was the number of enquiries and ramping up the biohazard element of QMB to support Covid trials outside of Hi Extrader, my understanding of timings from what has been said…delta strain is being manufactured by Nov/Dec to support characterisation study on Delta (alpha done, just awaiting report which seems likely early Nov based on comments from Dr Chiu). I’m assuming they’ll continue manufacturing it to support private sector anti viral trials next year and challenge studies post characterisation. Characterisation for delta would be Jan-May(ish) and CF has already mentioned that they’ve agreed c £5-6mn on top of the non-Covid £50mn for next FY from the characterisation work in H1, so timing for H2 to start running challenge trials seems realistic, although frustrating.
May also be why he is talking up anti viral work which could run off alpha characterisation approval which should be imminent??
Number of enquiries around Covid would suggest market is more anti-virals / therapeutics.
Other key element of Daily Telegraph article was the ramping up the biohazard element of QMB to support Covid trials outside of Royal Free - only logical reason for spending (and CF is frugal) is if QMB is going to support Covid studies. Would also explain need for another hotel as need to take non-Covid work out of QMB and support it elsewhere.
Thanks for this. From the Sun article
.."Patients won't be infected with Covid until next year but the facility is prepped for the trials.."
I think CF should be/should have been more realistic with CHIM timelines...and more informative about the ongoing delays, to help manage expectations.
Someone elsewhere has also pointed out that it's all gone quiet re CHIMagents (an option to acquire announced with much fanfare in July 2020), it seems per Companies House that Adrian Wildfire is still (with Martin Schutten) a 'controlling' shareholder - so presumably that's not happened, either.
I've written to ORPH to ask for clarification.
Looks like the Telegraph article from the weekend has been 'repurposed' for the American version of the The Sun, and syndicated to other News Corp titles, the New York Post and news.com.au
https://www.the-sun.com/health/3887694/lab-london-infecting-humans-covid/
https://nypost.com/2021/10/19/inside-the-only-facility-infecting-humans-with-covid-for-pay/
https://www.news.com.au/world/coronavirus/health/london-lab-prepares-to-pay-volunteers-to-be-infected-with-covid19-in-world-first/news-story/9f635ec82e87cee6ad0d445618b40061
Great to see more news coverage inside and outside the UK.